Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice

By L. Billings, S. Oddo, K. Green, James McGaugh, F. LaFerla. 2005

1,314 citations recorded by the source corpus.

Subfields: Economics and Econometrics

View Paper: https://www.semanticscholar.org/paper/57efb562b24b530e0ed9e016612c9e2fea8c4e10

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Selkoe
2. D. Holtzman
3. G. Bu
4. G. Shankar
5. James McGaugh
6. J. Herz
7. D. Walsh
8. Benno Roozendaal

Citations in the corpus

• Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. (2012, background): “3), which under certain conditions may be toxic (Billings et al. 2005).”
• Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006, background): “In the 3XTg-AD mouse model (Oddo et al., 2003), long-term retention memory deficits in the Morris water maze correlate with intraneuronal A at 4 months, an age when mice do not have amyloid deposits (Billings et al., 2005).”
• Glucocorticoids Increase Amyloid-β and Tau Pathology in a Mouse Model of Alzheimer’s Disease (2006, background): “Until 9 months of age, basal plasma corticosterone levels were unchanged in 3 Tg-AD mice compared with age-matched nontransgenic (NonTg) mice, despite a steady accumulation of A pathology over that period (Oddo et al., 2003; Billings et al., 2005).”
• Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014, neutral): “…29: (Urano and Tohda, 2010), 30: (Oddo et al., 2003), 31: (Clinton et al., 2007), 32: (Carroll et al., 2007), 33: (Gimenez-Llort et al., 2007), 34: (Billings et al., 2005), 35: (Nelson et al., 2007b), 36: (Pietropaolo et al., 2008), 37: (Filali et al., 2012), 38: (Arsenault et al., 2011), 39:…”
• Amyloid Precursor Protein Processing and Alzheimer’s Disease (2011, background): “Reducing levels of Aβ by immunotherapy prevents tau pathology from developing and abrogates spatial memory problems (Billings et al. 2005, Oddo et al. 2006).”
• Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy (2009, background): “However, it is possible that receptor-mediated clearance of Aβ into neurons can lead to intraneuronal Aβ accumulation, which is toxi”
• Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers (2006, background): “Moreover, immunizing the triple transgenic mice with anti-Aβ antibodies reduces Aβ accumulation and slows the emergence of tau-containing tangles, suggesting that the build-up of Aβ precedes tau aggregation (Oddo et al. 2004; Billings et al. 2005).”
• White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes (2018, neutral): “In animal models of AD, the white matter disruption and changes in myelin marker expression are among the earliest pathological changes [16, 30].”